Skip to main
  1. Stocks
  2. Beam Therapeutics
  3. Forecast
BEAM

Beam Therapeutics (BEAM) Stock Forecast & Price Target

Beam Therapeutics (BEAM) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Beam Therapeutics is supported by a compelling clinical and regulatory inflection in risto-cel, which met the pivotal BEACON trial’s primary endpoint of freedom from severe VOCs for ≥12 consecutive months, along with all primary safety and secondary efficacy endpoints, while safety remained consistent with prior data. The program’s profile is further strengthened by prior results showing mean HbF of 63.5% at Month 6 and rapid engraftment signals, and the company ended 3Q26 with $1.0B in cash and equivalents plus an additional $200MM expected from its Sixth Street facility, providing runway into mid-2029. Beyond SCD, the broader pipeline across BEAM-302, BEAM-304, and BEAM-301 adds multiple shots on goal, with updated BEAM-302 data showing durable biomarker improvements and basket BLA guidance potentially streamlining development in monogenic diseases.

Bears say

Beam Therapeutics is exposed to substantial fundamental risk because its valuation depends heavily on early-stage gene-editing programs that could suffer from poorer-than-expected preclinical or clinical data, off-target activity, or other safety signals. The company also faces meaningful regulatory and commercialization uncertainty, since novel medicines may require additional or longer-term data, may not gain approval, and may struggle to achieve favorable reimbursement or adoption. In addition, greater-than-expected competition, intellectual property risk, and negative industry headlines could materially reduce each product candidate’s market potential and limit long-term value creation.

Beam Therapeutics (BEAM) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beam Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Beam Therapeutics (BEAM) Analyst Forecast & Price Prediction

Get the latest Beam Therapeutics (BEAM) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Beam Therapeutics (BEAM)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beam Therapeutics (BEAM) Forecast

Analysts have given Beam Therapeutics (BEAM) a Buy based on their latest research and market trends.

According to 10 analysts, Beam Therapeutics (BEAM) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beam Therapeutics (BEAM)


Beam Therapeutics (BEAM) Analyst Forecast & Price Prediction

Get the latest Beam Therapeutics (BEAM) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Beam Therapeutics (BEAM)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BEAM stock data and trends